Migrastatin Analogues and Inhibition of Tumor Metastasis

米格拉他汀类似物及其对肿瘤转移的抑制

基本信息

  • 批准号:
    8111229
  • 负责人:
  • 金额:
    $ 33.48万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-15 至 2013-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Tumor metastasis is the major cause of death of cancer patients. Thus, prevention of tumor metastasis will significantly increase the survival rate of cancer patients, allow more moderate radiation or chemotherapy with less side- effects, and control the progression of tumors. One critical step of tumor metastasis is tumor cell migration and invasion. In this application, we focus on a new group of small molecules, the migrastatin analogues. We have shown that these small molecules are potent inhibitors of the migration of metastatic tumor cells, but not normal primary cells. We have shown that two of these migrastatin analogues reduced mouse breast tumor metastasis in a mouse model. We will perform preclinical discovery research and eventually develop these migrastatin analogues for cancer treatment/prevention. We have proposed three specific aims in this application. In the specific aim 1, we will focus on the molecular mechanism by which migrastatin analogues inhibit tumor cell migration. In the specific aim 2, we will examine the role of the target protein of migrastatin analogues in breast tumor cell migration, invasion, and metastasis. In the specific aim 3, we will investigate the effect of migrastatin analogues on the metastasis of human breast cancer cells in immune-compromised nude mice. The success of our study will provide a new therapeutic for cancer treatment, specifically for metastasis prevention. PUBLIC HEALTH RELEVANCE: The proposal investigates potential therapeutics for treatment of metastatic breast cancer. The spread or recurrence of breast cancer is every breast cancer patient's worst fear. Unfortunately, there is currently no curative treatment for breast cancer once it has metastasized. Therefore, there is a tremendous need for new treatments for metastatic (advanced stage) breast cancer. Since tumor cell migration is essential for breast tumor metastasis, cell migration inhibitors can be developed as new drugs to treat breast cancers. The migrastatin analogues hold much promise.
描述(申请人提供):肿瘤转移是癌症患者死亡的主要原因。因此,预防肿瘤转移将显着提高癌症患者的生存率,允许更温和且副作用更少的化疗,并控制肿瘤的进展。肿瘤转移的关键步骤之一是肿瘤细胞的迁移和侵袭。在此应用中,我们关注一组新的小分子,即迁移他汀类似物。我们已经证明,这些小分子是转移性肿瘤细胞迁移的有效抑制剂,但不是正常原代细胞。我们已经证明,其中两种迁移他汀类似物可以在小鼠模型中减少小鼠乳腺肿瘤转移。我们将进行临床前发现研究,并最终开发这些用于癌症治疗/预防的迁移他汀类似物。我们在此应用中提出了三个具体目标。在具体目标1中,我们将重点研究migrastatin类似物抑制肿瘤细胞迁移的分子机制。在具体目标2中,我们将研究migrastatin类似物的靶蛋白在乳腺肿瘤细胞迁移、侵袭和转移中的作用。在具体目标3中,我们将研究migrastatin类似物对免疫受损裸鼠体内人乳腺癌细胞转移的影响。我们研究的成功将为癌症治疗,特别是预防转移提供新的疗法。公共卫生相关性:该提案研究了治疗转移性乳腺癌的潜在疗法。乳腺癌的扩散或复发是每个乳腺癌患者最担心的事情。不幸的是,目前还没有针对转移的乳腺癌的治愈方法。因此,非常需要针对转移性(晚期)乳腺癌的新疗法。由于肿瘤细胞迁移对于乳腺肿瘤转移至关重要,因此可以开发细胞迁移抑制剂作为治疗乳腺癌的新药。米格拉他汀类似物有着广阔的前景。

项目成果

期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Mouse models for tumor metastasis.
Migrastatin analogues target fascin to block tumour metastasis.
  • DOI:
    10.1038/nature08978
  • 发表时间:
    2010-04-15
  • 期刊:
  • 影响因子:
    64.8
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Xin-Yun Huang其他文献

Xin-Yun Huang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Xin-Yun Huang', 18)}}的其他基金

Molecular Basis of B1-Adrenergic Receptor Function
B1-肾上腺素受体功能的分子基础
  • 批准号:
    10414984
  • 财政年份:
    2020
  • 资助金额:
    $ 33.48万
  • 项目类别:
Molecular Basis of B1-Adrenergic Receptor Function
B1-肾上腺素受体功能的分子基础
  • 批准号:
    10034746
  • 财政年份:
    2020
  • 资助金额:
    $ 33.48万
  • 项目类别:
Molecular Basis of B1-Adrenergic Receptor Function
B1-肾上腺素受体功能的分子基础
  • 批准号:
    10618897
  • 财政年份:
    2020
  • 资助金额:
    $ 33.48万
  • 项目类别:
Molecular Basis of B1-Adrenergic Receptor Function
B1-肾上腺素受体功能的分子基础
  • 批准号:
    10224279
  • 财政年份:
    2020
  • 资助金额:
    $ 33.48万
  • 项目类别:
Functions of G-proteins in Endothelial Cells
内皮细胞中 G 蛋白的功能
  • 批准号:
    9176372
  • 财政年份:
    2016
  • 资助金额:
    $ 33.48万
  • 项目类别:
Functions of G-proteins in Endothelial Cells
内皮细胞中 G 蛋白的功能
  • 批准号:
    9282797
  • 财政年份:
    2016
  • 资助金额:
    $ 33.48万
  • 项目类别:
Targeting fascin to block tumor metastasis
靶向肌成束蛋白阻断肿瘤转移
  • 批准号:
    9191345
  • 财政年份:
    2015
  • 资助金额:
    $ 33.48万
  • 项目类别:
The Rac-cGMP Signaling Pathway
Rac-cGMP 信号通路
  • 批准号:
    7939038
  • 财政年份:
    2009
  • 资助金额:
    $ 33.48万
  • 项目类别:
The Rac-cGMP Signaling Pathway
Rac-cGMP 信号通路
  • 批准号:
    8021806
  • 财政年份:
    2009
  • 资助金额:
    $ 33.48万
  • 项目类别:
The Rac-cGMP Signaling Pathway
Rac-cGMP 信号通路
  • 批准号:
    7748969
  • 财政年份:
    2009
  • 资助金额:
    $ 33.48万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 33.48万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.48万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 33.48万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.48万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 33.48万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.48万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 33.48万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 33.48万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 33.48万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.48万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了